Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H72O13 |
Molecular Weight | 785.0133 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@@](C)(O)CCC=C(C)C
InChI
InChIKey=RWXIFXNRCLMQCD-JBVRGBGGSA-N
InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27800005 | https://www.ncbi.nlm.nih.gov/pubmed/22403544 | https://www.ncbi.nlm.nih.gov/pubmed/24678300
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27800005 | https://www.ncbi.nlm.nih.gov/pubmed/22403544 | https://www.ncbi.nlm.nih.gov/pubmed/24678300
Ginsenoside Rg3 (Rg3) is one of the most effective steroidal saponins extracted from Ginseng, a common Traditional Chinese medicine (TCM) herb which tonifies Qi in TCM theory and inhibits tumors. Rg3 suppresses tumor growth and tumor angiogenesis. For its significant antitumor effects, Rg3 has been used in clinical trials in combination with chemotherapy regimens. 20(S) and 20(R) forms of ginsenosides are stereoisomers of each other that depend on the orientation of the C-20 hydroxyl in ginsenosides. In general, the 20(S) compounds have been shown to possess better anti-proliferative effects than their 20(R) counterparts whereas 20(R) compounds such as 20(R)-Rg3 have been shown to inhibit cancer cell invasion and metastasis. Ginsenoside Rg3 regulates voltage-gated ion channels such as Ca(2+), K(+), and Na(+) channels, and ligand-gated ion channels such as GABAA, 5-HT3, nicotinic acetylcholine, and N-methyl-D-aspartate (NMDA) receptors through interactions with various sites including channel blocker binding sites, toxin-binding sites, channel gating regions, and allosteric channel regulator binding sites when the respective ion channels or receptors are stimulated with depolarization or ligand treatment. Shenyi capsule which contains ginsenoside Rg3 as the main ingredient has been approved by China Food and Drug Administration (CFDA) to be used clinically for cancer treatment.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23717153 | https://www.ncbi.nlm.nih.gov/pubmed/24678300
Curator's Comment: No human data available.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL268 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26059856 |
|||
Target ID: CHEMBL2111392 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499684 |
|||
Target ID: CHEMBL4205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17959711 |
1.59 µM [IC50] | ||
Target ID: CHEMBL2221347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20399767 |
15.2 µM [EC50] | ||
Target ID: CHEMBL1899 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17257631/ |
27.6 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Shenyi capsule Approved UseShenyi capsule which contains ginsenoside Rg3 as the main ingredient has been approved by China Food and Drug Administration (CFDA) to be used clinically for cancer treatment Launch Date1999 |
|||
Primary | Shenyi capsule Approved UseShenyi capsule which contains ginsenoside Rg3 as the main ingredient has been approved by China Food and Drug Administration (CFDA) to be used clinically for cancer treatment Launch Date1999 |
|||
Primary | Shenyi capsule Approved UseShenyi capsule which contains ginsenoside Rg3 as the main ingredient has been approved by China Food and Drug Administration (CFDA) to be used clinically for cancer treatment Launch Date1999 |
|||
Primary | Shenyi capsule Approved UseShenyi capsule which contains ginsenoside Rg3 as the main ingredient has been approved by China Food and Drug Administration (CFDA) to be used clinically for cancer treatment Launch Date1999 |
Sample Use Guides
Effect of 400-mg Ginsenoside Rg3-enriched Korean red ginseng extract on two separate visits with a 7-day washout period was studied on measures of arterial stiffness and peripheral and central blood pressure (BP) parameters in healthy volunteers.
Pharmacokinetics of single oral dose of 3.2 mg/kg-1of 20 (R)-ginsenoside Rg3 was studied in human.
Route of Administration:
Oral
10-180 μg/ml Ginsenoside Rg3 significantly reduced both HUVEC and rat C6 glioma cell proliferation. The combination of Rg3 (50 uM) with cisplatin (10 uM) and doxorubicin (2 uM) was also more effective in the inhibition of prostate cancer cell growth and NF-kappaB activity than those by the treatment of Rg3 or chemotherapeutics alone.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000153733
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
DTXSID101316982
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
67991
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
14197-60-5
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
227D367Y57
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
9918693
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
SUB127965
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD